Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSD | P07339 | 11/20 | 0.47 |
| ▸ | NTSR2 | O95665 | 1/20 | 0.45 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.45 |
| ▸ | FURIN | P09958 | 1/20 | 0.45 |
| ▸ | PCSK6 | P29122 | 1/20 | 0.45 |
| ▸ | REN | P00797 | 1/20 | 0.43 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.43 |
| ▸ | ENPEP | Q07075 | 4/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30369179 | 0.93 | CTSD (0.48) | CTSDNTSR2NTSR1FURINPCSK6 | |
| SCHEMBL30578954 | 0.91 | CPB2 (0.47) | CPB2ENPEP | |
| SCHEMBL31514354 | 0.90 | RXFP1 (0.46) | CTSDFURINPCSK6 | |
| SCHEMBL29625510 | 0.90 | NTSR2 (0.48) | CTSDNTSR2NTSR1FURINPCSK6 | |
| SCHEMBL29464043 | 0.89 | CCNA2 (0.43) | CTSDNTSR2NTSR1FURINPCSK6 | |
| SCHEMBL29500572 | 0.89 | CCNA2 (0.43) | CTSDNTSR2NTSR1FURINPCSK6 | |
| SCHEMBL29489272 | 0.88 | CPB2 (0.45) | FURINCPB2ENPEP | |
| SCHEMBL31574021 | 0.86 | ENPEP (0.51) | ENPEP | |
| SCHEMBL31063765 | 0.85 | ENPEP (0.49) | NTSR2NTSR1CPB2ENPEP | |
| SCHEMBL31041715 | 0.85 | FURIN (0.46) | CTSDFURINREN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4159745-B1 | S100A8-INHIBITING PEPTIDE AND THERAPEUTIC DRUG FOR DISEASE WHICH CONTAINING SAME | UNIV TOKYO WOMENS MEDICAL (JP) | 2025-09-24 | — | — | EP | disclosed |
| US-20230220005-A1 | S100A8-INHIBITING PEPTIDE AND DISEASE THERAPEUTIC AGENT CONTAINING SAME | TOKYO WOMEN'S MEDICAL UNIVERSITY (JP) | 2023-07-13 | — | — | US | disclosed |
| EP-4159745-A1 | S100A8-INHIBITING PEPTIDE AND THERAPEUTIC DRUG FOR DISEASE WHICH CONTAINING SAME | Tokyo Women's Medical University (JP) | 2023-04-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230220005-A1 | S100A8-INHIBITING PEPTIDE AND DISEASE THERAPEUTIC AGENT CONTAINING SAME | S100A8, S100A11, S100A4 | CTSD 1443/4885NTSR2 1314/4885NTSR1 1150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.